###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
GSTT2 promoter polymorphisms and colorectal cancer risk
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 195 200 <span type="species:ncbi:9606">human</span>
Glutathione S-transferases are a group of enzymes that participate in detoxification and defense mechanisms against toxic carcinogens and other compounds. These enzymes play an important role in human carcinogenesis. In the present study, we sought to determine whether GSTT2 promoter single nucleotide polymorphisms (SNPs) are associated with colorectal cancer risk.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 92 98 92 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
A total of 436 colorectal cancer patients and 568 healthy controls were genotyped for three GSTT2 promoter SNPs (-537G>A, -277T>C and -158G>A), using real-time TaqMan assay and direct sequencing. An electrophoretic mobility shift assay (EMSA) was performed to determine the effects of polymorphisms on protein binding to the GSTT2 promoter.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 104 106 104 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 222 224 222 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 338 340 338 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 439 441 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
The -537A allele (-537G/A or A/A) was significantly associated with colorectal cancer risk (OR = 1.373, p = 0.025), while the -158A allele (-158G/A or A/A) was involved in protection against colorectal cancer (OR = 0.539, p = 0.032). Haplotype 2 (-537A, -277T, -158G) was significantly associated with colorectal cancer risk (OR = 1.386, p = 0.021), while haplotype 4 (-537G, -277C, -158A) protected against colorectal cancer (OR = 0.539, p = 0.032). EMSA data revealed lower promoter binding activity in the -537A allele than its -537G counterpart.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
Our results collectively suggest that SNPs and haplotypes of the GSTT2 promoter region are associated with colorectal cancer risk in the Korean population.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 844 845 844 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 979 980 979 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1093 1094 1093 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1095 1096 1095 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1078 1083 <span type="species:ncbi:9606">human</span>
Colorectal cancer (CRC), a predominant cause of tumor-related death in Western nations, is becoming more prevalent in Asian countries such as Korea [1,2]. Genetic and environmental factors are modulators of the carcinogenesis process [3]. Studies on the contribution of genetic polymorphisms to cancer development have examined numerous genes, including oncogenes, tumor suppressors, DNA repair genes and those encoding Phase I and Phase II enzymes [4]. Phase II enzymes attach to additional substrates in an attempt to detoxify the activated metabolite in preparation for final breakdown or excretion. Glutathione-S-transferases (GSTs) are a family of Phase II detoxification enzymes that protect cellular macromolecules by catalyzing the conjugation of glutathione (GSH) to a wide variety of endogenous and exogenous electrophilic compounds [5]. GSTs are divided into at least six classes (alpha, mu, pi, theta, omega and zeta), each of which consists of one or more isoforms [6]. GST polymorphisms are associated with bladder, colorectal, gastric, prostate and various other human cancers [5,7-11].
###end p 11
###begin p 12
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2</italic>
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 116 122 116 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 171 176 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 712 718 712 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 955 961 955 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1021 1027 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSST2 </italic>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1213 1219 1213 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 594 600 <span type="species:ncbi:9606">humans</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
###xml 1264 1269 <span type="species:ncbi:9606">human</span>
The theta class consists of two genes, GSTT1 and GSTT2, located at 22q11.2, and separated by about 50 kb. GSTT1 and GSTT2 share 55% amino acid sequence identity [12]. The GSTT1-null genotype is associated with increased CRC risk [7,13,14]. A common characteristic of the theta class is their affinity for the organic hydroperoxide species; for example, cumene hydroperoxide is a good substrate for GSTT2 [15]. Thus, GSTT2 activity is important for the protection of cells against toxic products of oxygen and lipid peroxidation [16], which represents a major source of endogenous DNA damage in humans that contributes significantly to cancer and other genetic diseases [17]. Pool-Zobel et al. [18] observed that GSTT2 involved in defense against oxidative stress in primary human colon cells is up-regulated upon incubation with butyrate. A comprehensive study of Phase I and Phase II metabolism gene polymorphisms revealed no significant contribution of GSTT2 polymorphism to CRC risk [19]. However, distinct effects of GSST2 promoter haplotypes on gene expression were observed with a luciferase reporter assay [20]. Genetic alterations may induce abnormal gene expression. To date, no case-control analysis of GSTT2 promoter polymorphisms has been performed in human cancers.
###end p 12
###begin p 13
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
In the present study, we sought to determine whether four GSTT2 promoter polymorphisms, -537G>A, -277T>C, -158G>A, and -129T>C, and their haplotypes are associated with CRC risk. We additionally employed EMSA to determine whether GSTT2 promoter polymorphisms affect the binding of putative transcription factors.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Samples and DNA extraction
###end title 15
###begin p 16
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 626 634 <span type="species:ncbi:9606">patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
Four hundred and thirty-six colorectal cancer samples were collected from the Seoul National University Hospital and the National Cancer Center Hospital, Korea. Clinical characteristics, including age, sex, tumor location, and TNM stage, were additionally analyzed for the association study with GSTT2 genotyping. DNA was extracted from normal colorectal tissues. Fresh cancer tissues were stored at -70degreesC in a liquid nitrogen tank. Normal population samples were obtained from 568 healthy Korean individuals as controls, and DNA was isolated from blood samples. All colorectal cancer samples were collected from Korean patients enrolled between 1990 and 2003 at Seoul National University and National Cancer Center. Normal controls were selected from cancer-free samples enrolled from the Cancer Cohort Study Branch of the National Cancer Center. The mean ages of colorectal cancer patients at diagnosis and normal subjects were 58.8 years (58.8 +/- 12.9 years) and 52.1 years (52.1 +/- 10.5 years), respectively.
###end p 16
###begin p 17
Total genomic DNA was extracted with TRIzol reagent, according to the manufacturer's instructions (Invitrogen, CA, USA). This study was approved by the institutional review board of the National Cancer Center and informed consent was obtained from all subjects prior to inclusion in the study.
###end p 17
###begin title 18
GSTT2 genotyping
###end title 18
###begin p 19
###xml 1021 1025 1020 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
The -537G>A (rs140186) and -277T>C (rs9624369) polymorphisms were screened using real-time TaqMan assay, and -158G>A and -129T>C polymorphisms were screened by direct sequencing. For the TaqMan assay, both PCR primers and MGB TaqMan probes were designed using the commercial Assay by Design service (Applied Biosystems, Foster City, CA, USA). One allelic probe was labeled with FAM dye, and the other with VIC. PCR was performed using the TaqMan Universal Master MIX without UNG in a 7900 HT fast real-time system (Applied Biosystems, Foster City, CA, USA). Data files were assessed using SDS2.1.1 software (Applied Biosystems, Foster City, CA, USA). We used BigDye Terminator and an ABI PRISM 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA) for direct sequencing analysis. Amplification for direct sequencing was performed in a final volume of 15 mul containing 10 ng genomic DNA, 10 pmol of each primer (forward: 5'-CCACTGGGTGAAACTCTAAG-3', reverse: 5'-GGACACCAGGTCAAGAAAC-3'), 0.25 mM each dNTP, 0.5 U of Taq polymerase and reaction buffer (Genecraft Ltd, Munster, Germany). Reactions were performed in a programmable thermal cycler (MWG Biotech AG, Eberberg, Germany) under the following conditions: denaturation for 5 min at 94degreesC, followed by 40 cycles at 94degreesC for 30 s, 55degreesC for 30 s, 72degreesC for 1 min, and a final extension of 10 min at 72degreesC.
###end p 19
###begin title 20
Microsatellite instability (MSI) analysis
###end title 20
###begin p 21
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
Two microsatellite markers (BAT-25 and BAT-26) were used to assess MSI status. DHPLC (denaturing high-performance liquid chromatography) and the capillary-based method were employed [2]. Cancer samples were classified as MSI when at least one MSI was evident in two markers. MSI data were obtained from 200 previously reported samples [2] and 236 patients analyzed in this study.
###end p 21
###begin title 22
Electrophoretic mobility shift assay (EMSA)
###end title 22
###begin p 23
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 334 335 334 335 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 384 385 384 385 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 462 463 462 463 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 513 514 513 514 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T</bold>
###xml 591 592 591 592 <bold xmlns:xlink="http://www.w3.org/1999/xlink">G</bold>
###xml 641 642 641 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 719 720 719 720 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 769 770 769 770 <bold xmlns:xlink="http://www.w3.org/1999/xlink">T</bold>
###xml 841 843 837 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1046 1048 1042 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
EMSA was performed with the Gel Shift Assay System (Promega Corporation, Madison, WI, USA). Briefly, the following consensus oligonucleotide pairs corresponding to the GSTT2 promoter sequence were synthesized (Bioneer, Seoul, South Korea) (bold letters specify polymorphisms): -537G (including the G allele) forward 5'-TAAGATCCCTTTTAGGGGATCCCATTCGCTC-3' and reverse 5'-GAGCGAATGGGATCCCCTAAAAGGGATCTTA-3', -537A (including the A allele) forward 5'-TAAGATCCCTTTTAGAGGATCCCATTCGCTC-3', and reverse 5'-GAGCGAATGGGATCCTCTAAAAGGGATCTTA-3'; -158G (including the G allele) forward 5'-AGGAACCGAAGGGGCGAGGCGGGTCCGGGGG-3' and reverse 5'-TCCTTGGCTTCCCCGCTCCGCCCAGGCCCCC-3', -158A (including the A allele) forward 5'-AGGAACCGAAGGGGCAAGGCGGGTCCGGGGG-3', and reverse 5'-TCCTTGGTTCCCCGTTCCGCCCAGGCCCCC-3'. Primer pairs were annealed and labeled with [gamma-32P]ATP (Amersham Biosciences, Buckinghamshire, UK). Binding reactions were performed using HeLa nuclear extracts (Promega Corporation, Madison, WI, USA), according to the manufacturer's instructions. The 32P-labeled probe (1 mul) was incubated with 5 mg of HeLa nuclear extracts for 1 h at room temperature. Following the binding reaction, DNA-protein complexes were resolved by electrophoresis on a 4% non-denaturing acrylamide gel, which was subsequently transferred to 3 M blotting paper, dried, and exposed to film.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 131 132 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 187 190 185 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 192 194 190 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D'</italic>
###xml 241 242 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 242 243 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 282 284 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 285 287 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 375 380 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 383 385 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 386 388 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 868 870 866 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
GSTT2 genotyping results were analyzed for categorical variables using the chi2 test, and for continuous variables using student's t-test (SPSS 12.0, Chicago, IL). We examined Lewontin's D' (|D'|) and the linkage disequilibrium coefficient, r2, between all pairs of biallelic loci [21,22]. Haplotypes of each individual were inferred with the algorithm developed by Stephens et al. [21,22], which uses a Bayesian approach incorporating prior expectations of haplotypic structure based on population genetics and the coalescent theory (PHASE version 2.0). The genotype and haplotype-specific risks were estimated as odds ratios (OR) with associated 95% confidence intervals (CI) by logistic regression (SPSS 12.0, Chicago, IL). The observed genotype frequencies were analyzed with a chi-square test to determine whether they were in Hardy-Weinberg equilibrium (HWE). A p value of less than 0.05 was considered statistically significant.
###end p 25
###begin title 26
Results and discussion
###end title 26
###begin p 27
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 322 328 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 499 500 499 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 581 582 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 589 595 589 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 771 777 771 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 921 922 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1058 1060 1058 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1075 1076 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1202 1204 1202 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1219 1220 1219 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1287 1289 1287 1289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1007 1015 <span type="species:ncbi:9606">patients</span>
###xml 1180 1188 <span type="species:ncbi:9606">patients</span>
We initially selected three single nucleotide polymorphisms (SNPs) within the GSTT2 promoter region (-537G>A, -277T>C and -129T>C) highlighted in an earlier study [20] and further identified a novel -158G>A polymorphism. The rare -129T>C polymorphism with less than 1% minor allele frequency (MAF) was excluded, and three GSTT2 promoter polymorphisms (-537G>A, -277T>C and -158G>A) were analyzed for CRC risk. The MAF values of the three SNPs were 0.42 (-537A), 0.07 (-277C) and 0.03 (-158A) (Table 1). In control samples, the genotype distribution did not deviate from HWE (Table 1). The GSTT2 genotype results were not influenced by other potential CRC risk factors, such as age, sex, location, and TNM stage (Table 2). Moreover, the MSI status was not associated with GSTT2 polymorphisms (Table 2). Genotypes were analyzed for association with CRC risk using logistic regression models adjusted for age and sex (Table 1). The frequency of the -537A allele (G/A or A/A) was significantly increased in CRC patients compared to healthy controls (OR = 1.373, p = 0.025, Table 1). In contrast, the -158A allele (G/A or A/A) was more frequently observed in healthy controls than CRC patients (OR = 0.539, p = 0.032, Table 1). Moreover, the -277T/C polymorphism was not related to CRC risk (p = 0.125).
###end p 27
###begin p 28
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 184 186 184 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 255 258 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 486 487 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 740 742 740 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 892 894 892 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 909 910 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1012 1014 1012 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1057 1059 1057 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Linkage disequilibrium (LD) was tested for all SNP pairs. Lewontin's D' values of the pairs were 0.965 (-537G>A:-277T>C), 1.000 (-537G>A:-158G>A) and 1.000 (-277T>C:-158G>A), and the r2 values were 0.043, 0.017, and 0.385, respectively. Good level of LD (D' > 0.965) was observed between all SNP pairs. Four haplotypes with more than 2% frequency were selected for haplotype association analysis. Haplotype frequencies were 0.511 (HT1), 0.422 (HT2), 0.033 (HT3), and 0.032 (HT4) (Table 3). Haplotypes were analyzed for association with CRC risk using logistic regression models adjusted for age and sex (Table 3). Haplotype 2 (HT2; -537A, -277T, -158G) was correlated with significantly increased CRC risk, compared to non-HT2 (OR = 1.386, p = 0.021, Table 3). In contrast, haplotype 4 (HT4; -537G, -277C, -158A) was associated with protection against CRC, compared with non-HT4 (OR = 0.539, p = 0.032, Table 3). No significant relationship with CRC risk was evident for haplotypes 1 (HT1; -537G, -277T, -158G) (p = 0.336) and 3 (HT3; -537G, -277C, -158G) (p = 0.984). The -537A polymorphism positively associated with CRC risk was only observed in HT2, while the -158A polymorphism with a protective role against cancer was present in HT4. Individual SNP analysis of -537G>A and -158G>A is almost consistent with HT2 and HT4, respectively. This may be due to limited individual SNP numbers.
###end p 28
###begin p 29
###xml 117 119 117 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 428 434 428 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
After Bonferroni correction (the threshold of significance was 0.017, 3 polymorphisms were analyzed), the associated p values did not retain significance. However, since SNPs within the same gene displayed good level of LD, test statistics for the 3 polymorphisms were not independent, and the significance of association with CRC risk is noteworthy. However, further functional evidence is required to confirm our results that GSTT2 promoter polymorphisms are associated with CRC risk.
###end p 29
###begin p 30
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1478 1484 1478 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 1584 1590 1584 1590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
Accordingly, to determine whether the two polymorphisms affect the binding of putative transcription factors, EMSA was performed using allele-specific consensus oligonucleotide probes. Upon incubation of radiolabeled oligonucleotides specific for -537G and -537A in the presence of HeLa nuclear extracts, the former oligonucleotide displayed stronger band intensity than the latter (Lanes 2 and 8) (Figure 1). To confirm the presence of the DNA-protein complex, competition assays were performed with increasing amounts of unlabeled oligonucleotides (10-, 50-, 100-fold excess). Band densities decreased with increasing concentrations of unlabeled specific competitor (Lanes 3-5 and Lanes 9-11). In the presence of unlabeled non-specific probes, such as a 100-fold excess of the -537A competitor, the -537G oligonucleotide remained unaffected (lane 6). However, the -537A oligonucleotide probe could not bind the transcription factor (lane 12), and displayed no band with a 100-fold excess of -537G probe. Therefore, we conclude that the -537G oligonucleotide has more specific DNA-protein binding capacity than the -537A probe. EMSA was performed to investigate the binding between the -537G and A alleles in HeLa nuclear extracts. The -537A allele displayed weak transcription factor binding activity compared to the -537G allele. The -158G/A polymorphism did not display differences in binding activity in EMSA. Our results strongly indicate that the -537G/A polymorphism of GSTT2 specifically influences transcription factor binding activity, leading to a decrease or increase in GSTT2 expression.
###end p 30
###begin p 31
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 691 697 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 498 503 <span type="species:ncbi:9606">human</span>
GSTT2 exhibits high glutathione peroxidase activity with cumene hydroperoxide as a substrate [15]. In human colon cancer cells, butyrate and flavonoids that contribute to detoxification of dietary carcinogens induce upregulation of GSTT2 to protect against toxic products of oxygen and lipid peroxidation [18,23]. This gene may have an important role in carcinogenesis and sensitivity of tumors against oxidation stress. GSTT2 promoter polymorphisms significantly reduce luciferase activity in two human cell lines (HEK239t and TE671) [18]. SNPs or mutations within the promoter region reportedly affect transcription activity and gene expression [24]. Therefore, SNPs and haplotypes of the GSTT2 promoter region result in distinct GSTT2 activities, and the -537A allele may be associated with cancer development arising from oxidation stress.
###end p 31
###begin title 32
Conclusion
###end title 32
###begin p 33
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 329 335 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 563 569 563 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 641 646 <span type="species:ncbi:9606">human</span>
In summary, case-control analysis of CRC patients reveals that GSTT2 polymorphisms are associated with CRC risk. Individual SNP analyses and haplotype results were consistent. EMSA results revealed lower promoter binding activity of the -537A allele, compared to the -537G allele. To our knowledge, this is the first report that GSTT2 promoter polymorphisms and their haplotypes are associated with colorectal cancer risk. Our data collectively suggest that GSTT2 promoter polymorphisms are involved in CRC development, and it would thus be beneficial to include GSTT2 promoter SNPs when screening for relationships between GST families and human cancers.
###end p 33
###begin title 34
Competing interests
###end title 34
###begin p 35
The author(s) declare that they have no competing interests.
###end p 35
###begin title 36
Authors' contributions
###end title 36
###begin p 37
SGJ, IJK, and HCK participated in the design of the study, and drafted and wrote the manuscript. SGJ, IJK, HCK, and HWP participated in the statistical analysis. SAA and HJY participated in the production of genotype data. SGJ and KK carried out the EMSA, and HRS and JSL participated in the acquisition and interpretation of data. JGP participated in the design and coordination of the study. All authors read and approved the final manuscript.
###end p 37
###begin title 38
Pre-publication history
###end title 38
###begin p 39
The pre-publication history for this paper can be accessed here:
###end p 39
###begin p 40

###end p 40
###begin title 41
Acknowledgements
###end title 41
###begin p 42
This work was supported by a research grant from the National Cancer Center, Korea and the BK21 project for Medicine, Dentistry and Pharmacy.
###end p 42
###begin article-title 43
2002 Annual report of the Korea Central Cancer Registry: Based on registered data from 139 hospitals
###end article-title 43
###begin article-title 44
Robust microsatellite instability (MSI) analysis by denaturing high-performance liquid chromatography (DHPLC)
###end article-title 44
###begin article-title 45
Cancer and phase II drug-metabolizing enzymes
###end article-title 45
###begin article-title 46
Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer
###end article-title 46
###begin article-title 47
Cancer drugs, genetic variation and the glutathione-S-transferase gene family
###end article-title 47
###begin article-title 48
Glutathione transferases
###end article-title 48
###begin article-title 49
Metabolic genotypes and risk for colorectal cancer
###end article-title 49
###begin article-title 50
Expression of glutathione S-transferases in normal gastric mucosa and in gastric tumors
###end article-title 50
###begin article-title 51
Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population
###end article-title 51
###begin article-title 52
N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer
###end article-title 52
###begin article-title 53
The role of glutathione in cancer
###end article-title 53
###begin article-title 54
###xml 62 67 <span type="species:ncbi:9606">human</span>
Molecular cloning of a cDNA and chromosomal localization of a human theta-class glutathione S-transferase gene (GSTT2) to chromosome 22
###end article-title 54
###begin article-title 55
Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers
###end article-title 55
###begin article-title 56
Glutathione S-transferase T1 and M1 genotypes in normal mucosa, transitional mucosa and colorectal adenocarcinoma
###end article-title 56
###begin article-title 57
###xml 22 27 <span type="species:ncbi:9606">human</span>
Characterization of a human class-Theta glutathione S-transferase with activity towards 1-menaphthyl sulphate
###end article-title 57
###begin article-title 58
###xml 51 56 <span type="species:ncbi:9606">human</span>
Purification and characterization of a recombinant human Theta-class glutathione transferase (GSTT2-2)
###end article-title 58
###begin article-title 59
Oxy radicals, lipid peroxidation and DNA damage
###end article-title 59
###begin article-title 60
###xml 73 78 <span type="species:ncbi:9606">human</span>
Butyrate may enhance toxicological defence in primary, adenoma and tumor human colon cells by favourably modulating expression of glutathione S-transferases genes, an approach in nutrigenomics
###end article-title 60
###begin article-title 61
A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer
###end article-title 61
###begin article-title 62
Promoter polymorphisms in glutathione-S-transferase genes affect transcription
###end article-title 62
###begin article-title 63
A new statistical method for haplotype reconstruction from population data
###end article-title 63
###begin article-title 64
A comparison of bayesian methods for haplotype reconstruction from population genotype data
###end article-title 64
###begin article-title 65
###xml 0 5 <span type="species:ncbi:3750">Apple</span>
###xml 40 45 <span type="species:ncbi:9606">human</span>
Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics
###end article-title 65
###begin article-title 66
Experimental analysis of the annotation of promoters in the public database
###end article-title 66
###begin title 67
Figures and Tables
###end title 67
###begin p 68
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">EMSA with HeLa nuclear extracts using -537G and -537A oligonucleotides</bold>
###xml 101 103 97 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
EMSA with HeLa nuclear extracts using -537G and -537A oligonucleotides. Binding activities of [gamma-32P] ATP-labeled -537G (lane 1-6) and -537A (lane 7-12) oligonucleotides. The assay was performed in the presence (+) or absence (-) of HeLa nuclear extracts. Unlabeled -537G or -537A oligonucleotides were used in competition assays. Each binding reaction contained 5 mg of HeLa nuclear extracts and labeled -537G (lanes 2-6) or -537A (lanes 8-12) oligonucleotides. Excess unlabeled oligonucleotides (10-, 50- and 100-fold) were included in the binding reactions as competitors (Lanes 3-5 and 9-11, respectively). In addition, we added a 100-fold excess of unlabeled -537A and -537G oligonucleotides to compete with -537G (Lane 6) and -537A (Lane 12) oligonucleotides. The binding activity of -537G was unaffected, even in the presence of a 100-fold excess of -537A competitor (lane 6). However, the -537A oligonucleotide could not bind transcription factor (lane 12), and displayed no band in the presence of a 100-fold excess of -537G probe.
###end p 68
###begin p 69
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
GSTT2 polymorphisms and colorectal cancer risk
###end p 69
###begin p 70
Adjusted for age and sex; HWE: Hardy-Weinberg equilibrium for controls; MAF: Minor allele frequency
###end p 70
###begin p 71
Dominant model: Homozygote of major allele vs. heterozygote and homozygote of minor allele
###end p 71
###begin p 72
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT2 </italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of colorectal cancer patients and GSTT2 genotypes
###end p 72
###begin p 73
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 23 25 21 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 31 32 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 32 33 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 54 55 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 55 56 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Student's t-test or chi2 test; p1: Co-dominant model; p2: Dominant model
###end p 73
###begin p 74
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Haplotype distribution in colorectal cancer patients and normal controls
###end p 74
###begin p 75
Adjusted for age and sex; Non-HT1 includes HT2, HT3 and HT4 but not HT1. Dominant model
###end p 75

